2023-504412-14-00CompletedPhase 1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants with Early Idiopathic Parkinson’s Disease
Source: EU CTIS (euclinicaltrials.eu) · Last updated 20 Dec 2023
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 4 Aug 2023
- Start date
- 1 Sept 2022
- Lead sponsor
- F. Hoffmann-La Roche AG
- Diseases
- Parkinson disease
- EU CT number
- 2023-504412-14-00
- EudraCT number
- 2021-002345-15
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 20
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Brain Research Center Amsterdam B.V. | Amsterdam | Netherlands | Completed |
| Stichting Radboud University Medical Center | Nijmegen | Netherlands | Completed |
| Brain Research Center Zwolle B.V. | Zwolle | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.